Publikationen

Publikationen

    2017

    • Paijo J, Kaever V, Kalinke U (2017) cGAMP Quantification in Virus-Infected Human Monocyte-Derived Cells by HPLC-Coupled Tandem Mass Spectrometry. Methods Mol Biol (1656): 153-166.

    • Krenn V, Perino G, Rüther W, Krenn VT, Huber M, Hügle T, Najm A, Müller S, Boettner F, Pessler F, Waldstein W, Kriegsmann J, Casadonte R, Häupl T, Wienert S, Krukemeyer MG, Sesselmann S, Sunitsch S, Tikhilov R, Morawietz L (2017) 15 years of the histopathological synovitis score, further development and review: A diagnostic score for rheumatology and orthopaedics. Pathol Res Pract 213(8): 874-881.

    • Zhao Y, Stepto H, Schneider CK (2017) Development of the First WHO Lentiviral Vector Standard: Towards the Production Control and Standardisation of Lentivirus based Gene Therapy Products. Hum Gene Ther Methods n/a(n/a): n/a.

    • Hirche C, Frenz T, Haas SF, Doring M, Borst K, Tegtmeyer PK, Brizic I, Jordan S, Keyser K, Chhatbar C, Pronk E, Lin S, Messerle M, Jonjic S, Falk CS, Trumpp A, Essers MAG, Kalinke U (2017) Systemic Virus Infections Differentially Modulate Cell Cycle State and Functionality of Long-Term Hematopoietic Stem Cells In~Vivo. Cell Rep 19(11): 2345--2356.

    • Lirussi D, Ebensen T, Schulze K, Trittel S, Duran V, Liebich I, Kalinke U, Guzman CA (2017) Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation. EBioMedicine (22): 100-111.

    • Thiemann S, Smit N, Roy U, Lesker TR, Galvez EJC, Helmecke J, Basic M, Bleich A, Goodman AL, Kalinke U, Flavell RA, Erhardt M, Strowig T (2017) Enhancement of IFNgamma Production by Distinct Commensals Ameliorates Salmonella-Induced Disease. Cell Host Microbe 21(6): 682--694.e5.

    • Akmatov MK, Rober N, Ahrens W, Flesch-Janys D, Fricke J, Greiser H, Gunther K, Kaaks R, Kemmling Y, Krone B, Linseisen J, Meisinger C, Moebus S, Obi N, Guzman CA, Conrad K, Pessler F (2017) Anti-nuclear autoantibodies in the general German population: prevalence and lack of association with selected cardiovascular and metabolic disorders-findings of a multicenter population-based study. Arthritis Res Ther 19(1): 127.

    • Matschulla T, Berry R, Gerke C, Döring M, Busch J, Paijo J, Kalinke U, Momburg F, Hengel H, Halenius A (2017) A highly conserved sequence of the viral TAP inhibitor ICP47 is required for freezing of the peptide transport cycle. Sci Rep 7(1): 2933.

    • González-Motos V, Jürgens C, Ritter B, Kropp KA, Durán V, Larsen O, Binz A, Ouwendijk WJD, Lenac Rovis T, Jonjic S, Verjans GMGM, Sodeik B, Krey T, Bauerfeind R, Schulz TF, Kaufer BB, Kalinke U, Proudfoot AEI, Rosenkilde MM, Viejo-Borbolla A (2017) Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathog 13(5): 1-28.

    • Akmatov MK, Koch N, Vital M, Ahrens W, Flesch-Janys D, Fricke J, Gatzemeier A, Greiser H, Günther K, Illig T, Kaaks R, Krone B, Kühn A, Linseisen J, Meisinger C, Michels K, Moebus S, Nieters A, Obi N, Schultze A, Six-Merker J, Pieper DH, Pessler F (2017) Determination of nasal and oropharyngeal microbiomes in a multicenter population-based study – findings from Pretest 1 of the German National Cohort. Sci Rep 7(1): 1855.

    • Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck H (2017) RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Sci Transl Med 9(386).

    • Ruangkiattikul N, Nerlich A, Abdissa K, Lienenklaus S, Suwandi A, Janze N, Laarmann K, Spanier J, Kalinke U, Weiss S, Goethe R (2017) cGAS-STING-TBK1-IRF3/7 Induced Interferon-β Contributes to the Clearing of Non Tuberculous Mycobacterial Infection in Mice. Virulence 1-13.

    • Akmatov MK, Riese P, May M, Jentsch L, Ahmed MW, Werner D, Rösel A, Tyler M, Pessler K, Prokein J, Bernemann I, Klopp N, Prochnow B, Trittel S, Tallam A, Illig T, Schindler C, Guzmán CA, Pessler F (2017) Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly individuals recruited from the general population. Hum Vaccin Immunother 0 1-10.

    • Preusse M, Schughart K, Pessler F (2017) Host Genetic Background Strongly Affects Pulmonary microRNA Expression before and during Influenza A Virus Infection. Front Immunol 8 246.

    • Hoffmann M, Crone L, Dietzel E, Paijo J, Gonzalez-Hernandez M, Nehlmeier I, Kalinke U, Becker S, Pohlmann S (2017) A polymorphism within the internal fusion loop of the Ebola virus glycoprotein modulates host cell entry. J Virol 91(9).

    • Pfaender S, Walter S, Grabski E, Todt D, Bruening J, Romero-Brey I, Gather T, Brown RJP, Hahn K, Puff C, Pfankuche VM, Hansmann F, Postel A, Becher P, Thiel V, Kalinke U, Wagner B, Bartenschlager R, Baumgärtner W, Feige K, Pietschmann T, Cavalleri JMV, Steinmann E (2017) Immune protection against reinfection with nonprimate hepacivirus. Proceedings of the National Academy of Sciences 114(12): E2430-E2439.

    • Karabaev BB, Beisheeva NJ, Satybaldieva AB, Ismailova AD, Pessler F, Akmatov MK (2017) Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency virus, Treponema pallidum, and co-infections among blood donors in Kyrgyzstan: a retrospective analysis (2013-2015). Infect Dis Poverty 6(1): 45.

    • Akmatov MK, Jentsch L, Riese P, May M, Ahmed MW, Werner D, Rosel A, Prokein J, Bernemann I, Klopp N, Prochnow B, Illig T, Schindler C, Guzman CA, Pessler F (2017) Motivations for (non)participation in population-based health studies among the elderly - comparison of participants and nonparticipants of a prospective study on influenza vaccination. BMC Med Res Methodol 17(1): 18.

    • Kindler E, Gil-Cruz C, Spanier J, Li Y, Wilhelm J, Rabouw HH, Züst R, Hwang M, V’kovski P, Stalder H, Marti S, Habjan M, Cervantes-Barragan L, Elliot R, Karl N, Gaughan C, van Kuppeveld FJM, Silverman RH, Keller M, Ludewig B, Bergmann CC, Ziebuhr J, Weiss SR, Kalinke U, Thiel V (2017) Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathog 13(2): 1-26.

    • Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzman CA, Kallen KJ, Fotin-Mleczek M, Kalinke U (2017) A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects. J Immunol 198(4): 1595-1605.

    • Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Tureci O, Kalinke U (2017) The European Regulatory Environment of RNA-Based Vaccines. Methods Mol Biol 1499 203--222.

    2016

    • Abou-El-Enein M, Schneider CK (2016) Deciphering the EU clinical trials regulation. Nat Biotechnol 34(3): 231-233.

    • Akmatov MK, Stumme M, Pessler F (2016) Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012. Clin Exp Rheumatol 34(3): 548-553.

    • Andzinski L, Spanier J, Kasnitz N, Kröger A, Jin L, Brinkmann MM, Kalinke U, Weiss S, Jablonska J, Lienenklaus S (2016) Growing tumors induce a local STING dependent type I IFN response in dendritic cells. International Journal of Cancer 139(6): 1350-1357.

    • Blank T, Detje CN, Spiess A, Hagemeyer N, Brendecke SM, Wolfart J, Staszewski O, Zoller T, Papageorgiou I, Schneider J, Paricio-Montesinos R, Eisel UL, Manahan-Vaughan D, Jansen S, Lienenklaus S, Lu B, Imai Y, Muller M, Goelz SE, Baker DP, Schwaninger M, Kann O, Heikenwalder M, Kalinke U, Prinz M (2016) Brain Endothelial- and Epithelial-Specific Interferon Receptor Chain 1 Drives Virus-Induced Sickness Behavior and Cognitive Impairment. Immunity 44(4): 901-912.

    • Castiglia V, Piersigilli A, Ebner F, Janos M, Goldmann O, Dambock U, Kroger A, Weiss S, Knapp S, Jamieson AM, Kirschning C, Kalinke U, Strobl B, Muller M, Stoiber D, Lienenklaus S, Kovarik P (2016) Type I Interferon Signaling Prevents IL-1beta-Driven Lethal Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. Cell Host Microbe 19(3): 375-387.

    • De Beuckelaer A, Pollard C, van Lint S, Roose K, van Hoecke L, Naessens T, Udhayakumar VK, Smet M, Sanders N, Lienenklaus S, Saelens X, Weiss S, Vanham G, Grooten J, De Koker S (2016) Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Mol Ther 24(11): 2012--2020.

    • Elsaman AM, Muhammad EM, Pessler F (2016) Sonographic Findings in Gouty Arthritis: Diagnostic Value and Association with Disease Duration. Ultrasound Med Biol 42(6): 1330-1336.

    • Frenz T, Grabski E, Buschjäger D, Vaas LAI, Burgdorf N, Schmidt RE, Witte T, Kalinke U (2016) CD4+ T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. J Allergy Clin Immunol 138(2): 586-589 e10.

    • Grine L, Steeland S, Van Ryckeghem S, Ballegeer M, Lienenklaus S, Weiss S, Sanders NN, Vandenbroucke RE, Libert C (2016) Topical imiquimod yields systemic effects due to unintended oral uptake. Sci Rep 6 20134.

    • Hendel N, Akmatov MK, Hamel J, Vogelberg C, Pessler F (2016) Exhaled breath analysis in childhood rheumatic disorders-a longitudinal study. J Breath Res 10(2): 021001.

    • Kochs G, Anzaghe M, Kronhart S, Wagner V, Gogesch P, Scheu S, Lienenklaus S, Waibler Z (2016) In Vivo Conditions Enable IFNAR-Independent Type I Interferon Production by Peritoneal CD11b+ Cells upon Thogoto Virus Infection. J Virol 90(20): 9330-9337.

    • Lambricht L, Vanvarenberg K, De Beuckelaer A, Van Hoecke L, Grooten J, Ucakar B, Lipnik P, Sanders NN, Lienenklaus S, Preat V, Vandermeulen G (2016) Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines. Mol Ther 24(9): 1686-1696.

    • Luckoff A, Caramoy A, Scholz R, Prinz M, Kalinke U, Langmann T (2016) Interferon-beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization. EMBO Mol Med 8(6): 670-678.

    • Maier BB, Hladik A, Lakovits K, Korosec A, Martins R, Kral JB, Mesteri I, Strobl B, Müller M, Kalinke U, Merad M, Knapp S (2016) Type I interferon promotes alveolar epithelial type II cell survival during pulmonary Streptococcus pneumoniae infection and sterile lung injury in mice. Eur J Immunol 46(9): 2175-2186.

    • Nuhn L, Vanparijs N, De Beuckelaer A, Lybaert L, Verstraete G, Deswarte K, Lienenklaus S, Shukla NM, Salyer ACD, Lambrecht BN, Grooten J, David SA, De Koker S, De Geest BG (2016) pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proceedings of the National Academy of Sciences 113(29): 8098-8103.

    • Paijo J, Döring M, Spanier J, Grabski E, Nooruzzaman M, Schmidt T, Witte G, Messerle M, Hornung V, Kaever V, Kalinke U (2016) cGAS Senses Human Cytomegalovirus and Induces Type I Interferon Responses in Human Monocyte-Derived Cells. PLoS Pathog 12(4): e1005546.

    • Peschke K, Achleitner M, Frenzel K, Gerbaulet A, Ada SR, Zeller N, Lienenklaus S, Lesche M, Poulet C, Naumann R, Dahl A, Ravens U, Gunther C, Muller W, Knobeloch KP, Prinz M, Roers A, Behrendt R (2016) Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity. J Immunol 197(6): 2157-2166.

    • Pfaender S, Grabski E, Detje CN, Riebesehl N, Lienenklaus S, Steinmann E, Kalinke U, Pietschmann T (2016) Hepatitis C Virus Stimulates Murine CD8alpha-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathog 12(7): e1005736.

    • Puttur F, Francozo M, Solmaz G, Bueno C, Lindenberg M, Gohmert M, Swallow M, Tufa D, Jacobs R, Lienenklaus S, Kühl A A, Borkner L, Cicin-Sain L, Holzmann B, Wagner H, Berod L, Sparwasser T (2016) Conventional Dendritic Cells Confer Protection against Mouse Cytomegalovirus Infection via TLR9 and MyD88 Signaling. Cell Rep 17(4): 1113 - 1127.

    • Samir M, Pessler F (2016) Small Non-coding RNAs Associated with Viral Infectious Diseases of Veterinary Importance: Potential Clinical Applications. Front. Vet. Sci. 3 22.

    • Samir M, Vaas LAI, Pessler F (2016) MicroRNAs in the Host Response to Viral Infections of Veterinary Importance. Front Vet Sci 3 86.

    • Schlett CL, Hendel T, Hirsch J, Weckbach S, Caspers S, Schulz-Menger J, Ittermann T, von Knobelsdorff-Brenkenhoff F, Ladd SC, Moebus S, Stroszczynski C, Fischer B, Leitzmann M, Kuhl C, Pessler F, Hartung D, Kemmling Y, Hetterich H, Amunts K, Günther M, Wacker F, Rummeny E, Kauczor HU, Forsting M, Völzke H, Hosten N, Reiser MF, Bamberg F (2016) Quantitative, Organ-Specific Interscanner and Intrascanner Variability for 3 T Whole-Body Magnetic Resonance Imaging in a Multicenter, Multivendor Study. Invest Radiol 51(4): 255-265.

    • Schweitzer A, Pessler F, Akmatov MK (2016) Impact of rotavirus vaccination on coverage and timing of pentavalent vaccination – Experience from 2 Latin American countries. Human Vaccines & Immunotherapeutics 0 1-7.

    • Weissmuller S, Kronhart S, Kreuz D, Schnierle B, Kalinke U, Kirberg J, Hanschmann KM, Waibler Z (2016) TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One 11(3): e0149093.

    • de Araujo LS, Vaas LA, Ribeiro-Alves M, Geffers R, Mello FC, de Almeida AS, Moreira AD, Kritski AL, Lapa E.SilvaJR, Moraes MO, Pessler F, Saad MH (2016) Transcriptomic Biomarkers for Tuberculosis: Evaluation of DOCK9. EPHA4, and NPC2 mRNA Expression in Peripheral Blood. Front Microbiol 7 1586.

    2015

    • Abd-Elshafy DN, Muller-Ladner U, Neumann E, Anggakusuma., Bahgat MM, Pessler F, Behrendt P (2015) Cell culture-derived HCV cannot infect synovial fibroblasts. Sci Rep 5 18043.

    • Abd-Elshafy DN, Muller-Ladner U, Neumann E, Anggakusuma., Bahgat MM, Pessler F, Behrendt P (2015) Erratum: Cell culture-derived HCV cannot infect synovial fibroblasts. Sci Rep 6 21441.

    • Akmatov MK, Kimani-Murage E, Pessler F, Guzman CA, Krause G, Kreienbrock L, Mikolajczyk RT (2015) Evaluation of invalid vaccine doses in 31 countries of the WHO African Region. Vaccine 33(7): 892-901.

    • Akmatov MK, Rubsamen N, Schultze A, Kemmling Y, Obi N, Gunther K, Ahrens W, Pessler F, Krause G, Mikolajczyk RT (2015) Diverse recruitment strategies result in different participation percentages in a web-based study, but in similar compliance. Int J Public Health 60(8): 937-943.

    • Brinkmann MM, Dag F, Hengel H, Messerle M, Kalinke U, Cicin-Sain L (2015) Cytomegalovirus immune evasion of myeloid lineage cells. Med Microbiol Immunol 204(3): 367-382.

    • Crouse J, Kalinke U, Oxenius A (2015) Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol 15(4): 231-242.

    • Detje CN, Lienenklaus S, Chhatbar C, Spanier J, Prajeeth CK, Soldner C, Tovey MG, Schluter D, Weiss S, Stangel M, Kalinke U (2015) Upon intranasal VSV infection astrocytes in the olfactory bulb are important IFN-beta producers that protect from lethal encephalitis. J Virol 89(5): 2731-2738.

    • Fischbach H, Doring M, Nikles D, Lehnert E, Baldauf C, Kalinke U, Tampe R (2015) Ultrasensitive quantification of TAP-dependent antigen compartmentalization in scarce primary immune cell subsets. Nat Commun 6 6199.

    • Frenz T, Grabski E, Duran V, Hozsa C, Stepczynska A, Furch M, Gieseler RK, Kalinke U (2015) Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers. Eur J Pharm Biopharm 97(Pt A): 13-17.

    • Grabski E, Wappler I, Pfaender S, Steinmann E, Haid S, Dzionek A, Pietschmann T, Kalinke U (2015) Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus induced interferon-alpha responses of plasmacytoid dendritic cells. J Virol 89(6): 3200-3208.

    • Luciani F, Galluzzo S, Gaggioli A, Kruse NA, Venneugues P, Schneider CK, Pini C, Melchiorri D (2015) Implementing quality by design for biotech products: are regulators on track?. MAbs 7(3): 451-455.

    • Malczyk AH, Kupke A, Prufer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Shams Eldin H, Schmidt J, Vergara-Alert J, Suzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Muhlebach MD (2015) A highly immunogenic and protective MERS-Coronavirus vaccine based on recombinant MV vaccine platform. J Virol 89(22): 11654-11667.

    • Pfefferkorn C, Kallfass C, Lienenklaus S, Spanier J, Kalinke U, Rieder M, Conzelmann KK, Michiels T, Staeheli P (2015) Abortively infected astrocytes appear to represent the main source of interferon-β in the virus-infected brain. J Virol 90(4): 2031-2038.

    • Preusse M, Schughart K, Wilk E, Klawonn F, Pessler F (2015) Hematological parameters in the early phase of influenza A virus infection in differentially susceptible inbred mouse strains. BMC Res Notes 8 225.

    • Salmikangas P, Menezes-Ferreira M, Reischl I, Tsiftsoglou A, Kyselovic J, Borg JJ, Ruiz S, Flory E, Trouvin J, Celis P, Ancans J, Timon M, Pante G, Sladowski D, Lipnik-Stangelj M, Schneider CK (2015) Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. Regen Med 10(1): 65-78.

    • Schneider CK, Weise M (2015) Regulatorische Aspekte zu Biosimilars: Mythen und Fakten. Z Rheumatol 74(8): 695-700.

    • Schweitzer A, Akmatov MK, Kindler F, Kemmling Y, Kreienbrock L, Krause G, Pessler F (2015) The impact of distance and duration of travel on participation rates and participants' satisfaction: results from a pilot study at one study centre in Pretest 2 of the German National Cohort. BMJ Open 5(8): e007461.

    • Schweitzer A, Della Beffa C, Akmatov MK, Narchi H, Abaev YK, Sherry DD, Pessler F (2015) Primary Osteomyelitis of the Sternum in the Pediatric Age Group: Report of a New Case and Comprehensive Analysis of Seventy-four Cases. Pediatr Infect Dis J 34(4): e92-e101.

    • Schweitzer A, Krause G, Pessler F, Akmatov MK (2015) Improved coverage and timing of childhood vaccinations in two post-Soviet countries, Armenia and Kyrgyzstan. BMC Public Health 155(1): 798.

    • Skripuletz T, Salinas Tejedor L, Prajeeth CK, Hansmann F, Chhatbar C, Kucman V, Zhang N, Raddatz BB, Detje CN, Suhs KW, Pul R, Gudi V, Kalinke U, Baumgartner W, Stangel M (2015) The antiviral drug ganciclovir does not inhibit microglial proliferation and activation. Sci Rep 5 14935.

    • Vogel S, Grabski E, Buschjager D, Klawonn F, Doring M, Wang J, Fletcher E, Bechmann I, Witte T, Durisin M, Schraven B, Mangsbo SM, Schonfeld K, Czeloth N, Kalinke U (2015) Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep 5 18308.

    • Waffarn EE, Hastey CJ, Dixit N, Choi YS, Cherry S, Kalinke U, Simon SI, Baumgarth N (2015) Infection-induced type I interferons activate CD11b on B-1 cells for subsequent lymph node accumulation. Nature Communications 6 8991.

    • Wang H, El Maadidi S, Fischer J, Grabski E, Dickhofer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Loffler MW, Wiese M, Pichulik T, Mullhaupt B, Semela D, Dufour JF, East German, Swiss Hepatitis C.VirusStudyGroups, Bochud PY, Bowie AG, Kalinke U, Berg T, Weber AN (2015) A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatol 62(5): 1375-1387.

    2014

    • Abou-El-Enein M, Bauer G, Reinke P, Renner M, Schneider CK (2014) A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med d20(11): 632-642.

    • Akmatov MK, Mehraj J, Gatzemeier A, Strompl J, Witte W, Krause G, Pessler F (2014) Serial home-based self-collection of anterior nasal swabs to detect Staphylococcus aureus carriage in a randomized population-based study in Germany. Int J Infect Dis 25 4-10.

    • Arnold P, Himmels P, Weiss S, Decker TM, Markl J, Gatterdam V, Tampe R, Bartholomaeus P, Dietrich U, Durr R (2014) Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Retrovirology 11 42.

    • Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jonsson G, Holzel M, Tuting T (2014) Immune-cell poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 4(6): 674-687.

    • Bartholomaeus P, Semmler LY, Bukur T, Boisguerin V, Romer PS, Tabares P, Chuvpilo S, Tyrsin DY, Matskevich A, Hengel H, Castle J, Hunig T, Kalinke U (2014) Cell Contact-Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response. J Immunol 192(5): 2091-2098.

    • Borg JJ, Serracino-Inglott A, Azzopardi LM, Schneider CK (2014) Comment On: "EU's New Pharmacovigilance Legislation: Considerations for Biosimilars". Drug Saf 37(2): 123-124.

    • Castell S, Akmatov MK, Obi N, Flesh-Janys D, Nieters A, Kemmling Y, Pessler F, Krause G (2014) Test-retest reliability of an infectious disease questionnaire and evaluation of self-assessed vulnerability to infections : Findings of Pretest 2 of the German National Cohort. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 57(11): 1300-1307.

    • Conrad E, Resch TK, Gogesch P, Kalinke U, Bechmann I, Bogdan C, Waibler Z (2014) Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice. Hepatology 59(4): 1555-1563.

    • Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A (2014) Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1. Immunity 40(6): 961-973.

    • Doring M, Lessin I, Frenz T, Spanier J, Kessler A, Tegtmeyer P, Dag F, Thiel N, Trilling M, Lienenklaus S, Weiss S, Scheu S, Messerle M, Cicin-Sain L, Hengel H, Kalinke U (2014) M27 expressed by cytomegalovirus counteracts effective type I IFN induction of myeloid cells, but not of plasmacytoid dendritic cells. J Virol 88(23): 13638-13650.

    • Fleige H, Ravens S, Moschovakis GL, Bolter J, Willenzon S, Sutter G, Haussler S, Kalinke U, Prinz I, Forster R (2014) IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med 211(4): 643-651.

    • Frentzen A, Kusuma A, Guerlevik E, Hueging K, Knocke S, Ginkel C, Brown RJ, Heim M, Dill MT, Kroger A, Kalinke U, Kaderali L, Kuehnel F, Pietschmann T (2014) Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology 59(1): 78-88.

    • Frenz T, Graalmann L, Detje CN, Doring M, Grabski E, Scheu S, Kalinke U (2014) Independent of Plasmacytoid Dendritic Cell (pDC) infection, pDC Triggered by Virus-Infected Cells Mount Enhanced Type I IFN Responses of Different Composition as Opposed to pDC Stimulated with Free Virus. J Immunol 193(5): 2496-2503.

    • Gabaev I, Elbasani E, Ameres S, Steinbruck L, Stanton R, Doring M, Lenac Rovis T, Kalinke U, Jonjic S, Moosmann A, Messerle M (2014) Expression of the Human Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T Cells. J Virol 88(24): 14326-14339.

    • Haque A, Best SE, Montes de Oca M, James KR, Ammerdorffer A, Edwards CL, de Labastida Rivera F, Amante FH, Bunn PT, Sheel M, Sebina I, Koyama M, Varelias A, Hertzog PJ, Kalinke U, Gun SY, Renia L, Ruedl C, Macdonald KP, Hill GR, Engwerda CR (2014) Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity. J Clin Invest 124(6): 2483-2496.

    • Kuhn A, Nieters A, Kottgen A, Goek ON, Michels K, Nothlings U, Jacobs G, Meisinger C, Pessler F, Akmatov MF, Kuhnisch J, Moebus S, Glocker E, Naus S, Keimling M, Leitzmann M, Linseisen J, Sarioglu H, von Toerne C, Hauck SM, Wallaschofski H, Wichmann HE, Illig T (2014) Feasibility and quality development of biomaterials in the pretest studies of the German National Cohort. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(11): 1255-1263.

    • Lebel ME, Daudelin JF, Chartrand K, Tarrab E, Kalinke U, Savard P, Labrecque N, Leclerc D, Lamarre A (2014) Nanoparticle Adjuvant Sensing by TLR7 Enhances CD8+ T Cell-Mediated Protection from Listeria Monocytogenes Infection. J Immunol 192(3): 1071-1078.

    • Liehl P, Zuzarte-Luis V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassnig C, Muller M, Kalinke U, Saeed M, Chora AF, Golenbock DT, Strobl B, Prudencio M, Coelho LP, Kappe SH, Superti-Furga G, Pichlmair A, Vigario AM, Rice CM, Fitzgerald KA, Barchet W, Mota MM (2014) Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med 20(1): 47-53.

    • Mall S, Akmatov MK, Schultze A, Ahrens W, Obi N, Pessler F, Krause G (2014) Web-based questionnaires to capture acute infections in long-term cohorts : Findings of a feasibility study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(11): 1308-1314.

    • Mehraj J, Akmatov MK, Strompl J, Gatzemeier A, Layer F, Werner G, Pieper DH, Medina E, Witte W, Pessler F, Krause G (2014) Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus Nasal Carriage in a Random Sample of Non-Hospitalized Adult Population in Northern Germany. PLoS One 9(9): e107937.

    • Nair S, Michaelsen-Preusse K, Finsterbusch K, Stegemann-Koniszewski S, Bruder D, Grashoff M, Korte M, Koster M, Kalinke U, Hauser H, Kroger A (2014) Interferon regulatory factor-1 protects from fatal neurotropic infection with vesicular stomatitis virus by specific inhibition of viral replication in neurons. PLoS Pathog 10(3): e1003999.

    • Narayanan G, Cossu G, Galli MC, Flory E, Ovelgonne H, Salmikangas P, Schneider CK, Trouvin JH (2014) Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European union. Hum Gene Ther Clin Dev 25(1): 1-6.

    • Novoselova N, Beffa CD, Wang J, Li J, Pessler F, Klawonn F (2014) HUM Calculator and HUM package for R: easy-to-use software tools for multicategory receiver operating characteristic analysis. Bioinformatics 30(11): 1635-1636.

    • Pessler F, Ogdie AR, Mayer CT, Kretzschmar WW, Dai L, Elsaman AM, Einhorn E, Krenn V, Schumacher HR (2014) Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+ or CD38+ cells. Amyloid 21(1): 28-34.

    • Schultze A, Akmatov MK, Andrzejak M, Karras N, Kemmling Y, Maulhardt A, Wieghold S, Ahrens W, Gunther K, Schlenz H, Krause G, Pessler F (2014) Comparison of stool collection on site versus at home in a population-based study : Feasibility and participants' preference in Pretest 2 of the German National Cohort. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(11): 1264-1269.

    • Schultze A, Akmatov MK, Castell S, Karch A, Ahrens W, Gunther K, Schlenz H, Flesch-Janys D, Obi N, Pessler F, Krause G (2014) Collection of vaccination data in the German National Cohort : Findings of a feasibility study in three study centers. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(11): 1292-1299.

    • Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S (2014) Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides-Harmonized Terminology and Tactical Recommendations. Aaps J 16(4): 658-673.

    • Sievers C, Akmatov MK, Kreienbrock L, Hille K, Ahrens W, Gunther K, Flesch-Janys D, Obi N, Michels KB, Fricke J, Greiser KH, Kaaks R, Peter HH, Pessler F, Nieters A, Krause G (2014) Evaluation of a questionnaire to assess selected infectious diseases and their risk factors : Findings of a multicenter study. Evaluation of a questionnaire to assess selected infectious diseases and their risk factors : Findings of a multicenter study 57(11): 1283-1291.

    • Spanier J, Lienenklaus S, Paijo J, Kessler A, Borst K, Heindorf S, Baker DP, Kroger A, Weiss S, Detje CN, Staeheli P, Kalinke U (2014) Concomitant TLR/RLH Signaling of Radioresistant and Radiosensitive Cells Is Essential for Protection against Vesicular Stomatitis Virus Infection. J Immunol 193(6): 3045-3054.

    • Svitek N, Gerhauser I, Goncalves C, Grabski E, Doring M, Kalinke U, Anderson DE, Cattaneo R, von Messling V (2014) Morbillivirus Control of the Interferon Response: Relevance of STAT2 and mda5 but not STAT1 for Canine Distemper Virus Virulence in Ferrets. J Virol 88(5): 2941-2950.

    • Volz A, Langenmayer M, Jany S, Kalinke U, Sutter G (2014) Rapid expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with Modified Vaccinia virus Ankara. J Virol 88(18): 10946-10957.

    • Weber E, Finsterbusch K, Lindquist R, Nair S, Lienenklaus S, Gekara NO, Janik D, Weiss S, Kalinke U, Overby AK, Kroger A (2014) Type I interferon protects mice from fatal neurotropic infection with Langat virus by systemic and local anti-viral response. J Virol 88(21): 12202-12212.

    • Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK (2014) Biosimilars: the science of extrapolation. Blood 124(22): 3191-3196.

    • Zheng LS, Hitoshi S, Kaneko N, Takao K, Miyakawa T, Tanaka Y, Xia H, Kalinke U, Kudo K, Kanba S, Ikenaka K, Sawamoto K (2014) Mechanisms for Interferon-alpha-Induced Depression and Neural Stem Cell Dysfunction. Stem cell reports 3(1): 73-84.

    • Zust R, Toh YX, Valdes I, Cerny D, Heinrich J, Hermida L, Marcos E, Guillen G, Kalinke U, Shi PY, Fink K (2014) Type I IFN signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J Virol 88(13): 7276-7285.

    • van Aerts LA, De Smet K, Reichmann G, Willem van der Laan J, Schneider CK (2014) Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union. mAbs 6(5).

    2013

    • Aiuti A, Cossu G, de Felipe P, Galli MC, Narayanan G, Renner M, Stahlbom A, Schneider CK, Voltz-Girolt C (2013) The Committee for Advanced Therapies' (CAT) reflection paper on management of clinical risks deriving from insertional mutagenesis. Hum Gene Ther Clin Dev 24(2): 47-54.

    • Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Buscher D, Fibbe W, Foussat A, Kwa M, Lantz O, Maciulaitis R, Palomaki T, Schneider CK, Sensebe L, Tachdjian G, Tarte K, Tosca L, Salmikangas P (2013) Risk of tumorigenicity in mesenchymal stromal cell-based therapies-Bridging scientific observations and regulatory viewpoints. Cytotherapy 15(7): 753-759.

    • Beffa CD, Slansky E, Pommerenke C, Klawonn F, Li J, Dai L, Schumacher Jr HR, Pessler F (2013) The relative composition of the inflammatory infiltrate as an additional tool for synovial tissue classification. PLoS One 8(8): e72494.

    • Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U (2013) The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 31(10): 880-882.

    • Bunse CE, Borchers S, Varanasi PR, Tischer S, Figueiredo C, Immenschuh S, Kalinke U, Kohl U, Goudeva L, Maecker-Kolhoff B, Ganser A, Blasczyk R, Weissinger EM, Eiz-Vesper B (2013) Impaired Functionality of Antiviral T Cells in G-CSF Mobilized Stem Cell Donors: Implications for the Selection of CTL Donor. PLoS One 8(12): e77925.

    • Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, Salmonson T, Schneider CK, Rasi G (2013) The risks of risk aversion in drug regulation. Nat Rev Drug Discov 12(12): 907-916.

    • Elsaman AM, Radwan AR, Akmatov MK, Della Beffa C, Walker A, Mayer CT, Dai L, Nativ S, Rygg M, Atsali E, Saijo K, Ogdie AR, Srinivasulu N, Fathi N, Ralph Schumacher H, Pessler F (2013) Amyloid arthropathy associated with multiple myeloma: A systematic analysis of 101 reported cases. Semin Arthritis Rheum 43(3): 405-412.

    • Goulet ML, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, Janelle V, Arguello M, Paquet M, Ghneim K, Richards S, Smith A, Wilkinson P, Cameron M, Kalinke U, Qureshi S, Lamarre A, Haddad EK, Sekaly RP, Peri S, Balachandran S, Lin R, Hiscott J (2013) Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity. PLoS pathogens 9(4): e1003298.

    • Hogner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, Walmrath HD, Bodner J, Gattenlohner S, Lewe-Schlosser P, Matrosovich M, Seeger W, Lohmeyer J, Herold S (2013) Macrophage-expressed IFN-beta Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia. PLoS Pathog 9(2): e1003188.

    • Hogner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, Walmrath HD, Bodner J, Gattenlohner S, Lewe-Schlosser P, Matrosovich M, Seeger W, Lohmeyer J, Herold S (2013) Correction: Macrophage-expressed IFN-beta Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia. PLoS Pathog 12(6): e1005716.

    • Joshi R, Feldmann V, Koestner W, Detje C, Gottschalk S, Mayer HA, Sauer MG, Engelmann J (2013) Multifunctional silica nanoparticles for optical and magnetic resonance imaging. Biol Chem 394(1): 125-135.

    • Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I, Leufkens HG, Muller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL, Salmonson T, Schneider CK (2013) Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov 12(9): 719.

    • Prete F, Catucci M, Labrada M, Gobessi S, Castiello MC, Bonomi E, Aiuti A, Vermi W, Cancrini C, Metin A, Hambleton S, Bredius R, Notarangelo LD, van der Burg M, Kalinke U, Villa A, Benvenuti F (2013) Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. J Exp Med 210(2): 355-374.

    • Preusse M, Tantawy MA, Klawonn F, Schughart K, Pessler F (2013) Infection- and procedure-dependent effects on pulmonary gene expression in the early phase of influenza A virus infection in mice. BMC Microbiol 13 293.

    • Schneider CK (2013) Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 72(3): 315-318.

    • Siegfried A, Berchtold S, Manncke B, Deuschle E, Reber J, Ott T, Weber M, Kalinke U, Hofer MJ, Hatesuer B, Schughart K, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Weber F, Hornef MW, Autenrieth IB, Bohn E (2013) IFIT2 Is an Effector Protein of Type I IFN-Mediated Amplification of Lipopolysaccharide (LPS)-Induced TNF-alpha Secretion and LPS-Induced Endotoxin Shock. J Immunol 191(7): 3913-3921.

    • Tsiftsoglou AS, Ruiz S, Schneider CK (2013) Development and regulation of biosimilars: current status and future challenges. BioDrugs 27(3): 203-211.

    • Vestergaard HT, Apote LD, Schneider CK, Herberts C (2013) The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm. Mol Ther 21(7): 1294-1296.

    2012

    • Bache C, Spreitzer I, Becker B, Loeschner B, Rosskopf U, Hanschmann KM, Schwanig M, Schneider CK, Lieb B, Montag T (2012) Bordetella Pertussis Toxin does not induce the release of pro-inflammatory cytokines in human whole blood. Med Microbiol Immunol 201(3): 327-335.

    • Baranek T, Manh TP, Alexandre Y, Maqbool MA, Cabeza JZ, Tomasello E, Crozat K, Bessou G, Zucchini N, Robbins SH, Vivier E, Kalinke U, Ferrier P, Dalod M (2012) Differential responses of immune cells to type I interferon contribute to host resistance to viral infection. Cell Host Microbe 12(4): 571-584.

    • Ejaz A, Steinmann E, Banki Z, Anggakusuma, Khalid S, Lengauer S, Wilhelm C, Zoller H, Schloegl A, Steinmann J, Grabski E, Kleines M, Pietschmann T, Stoiber H (2012) Specific acquisition of functional CD59 but not CD46 or CD55 by hepatitis C virus. PLoS One 7(9): e45770.

    • Kalinke U, Prinz M (2012) Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS. Immunol Cell Biol 90(5): 505-509.

    • Kernbauer E, Maier V, Stoiber D, Strobl B, Schneckenleithner C, Sexl V, Reichart U, Reizis B, Kalinke U, Jamieson A, Mueller M, Decker T (2012) Conditional Stat1 Ablation Reveals the Importance of Interferon Signaling for Immunity to Listeria monocytogenes Infection. PLoS Pathog 8(6): e1002763.

    • Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, Hanschmann KM, Lehmann MH, Kalinke U, Sutter G (2012) Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS pathogens 8(3): e1002557.

    • Maciulaitis R, D'Apote L, Buchanan A, Pioppo L, Schneider CK (2012) Clinical development of advanced therapy medicinal products in europe: evidence that regulators must be proactive. Mol Ther 20(3): 479-482.

    • Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Muller M, Sexl V, Stoiber D (2012) Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 1(7): 1027-1037.

    • Schneider CK, Borg JJ, Ehmann F, Ekman N, Heinonen E, Ho K, Hoefnagel MH, van der Plas RM, Ruiz S, van der Stappen AJ, Thorpe R, Tiitso K, Tsiftsoglou AS, Vleminckx C, Waxenecker G, Welin M, Weise M, Trouvin JH (2012) In support of the European Union biosimilar framework. Nat Biotechnol 30(8): 745-748.

    • Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, Weise M, Thirstrup S (2012) Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 30(12): 1179-1185.

    • Schwandt T, Schumak B, Gielen GH, Jungerkes F, Schmidbauer P, Klocke K, Staratschek-Jox A, van Rooijen N, Kraal G, Ludwig-Portugall I, Franken L, Wehner S, Kalff JC, Weber O, Kirschning C, Coch C, Kalinke U, Wenzel J, Kurts C, Zawatzky R, Holzmann B, Layland L, Schultze JL, Burgdorf S, den Haan JM, Knolle PA, Limmer A (2012) Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis. Embo J 31(1): 201-213.

    • Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK (2012) Biosimilars: what clinicians should know. Blood 120(26): 5111-5117.

    • Weissmueller S, Semmler LY, Kalinke U, Christians S, Mueller-Berghaus J, Waibler Z (2012) ICOS-LICOS interaction is critically involved in TGN1412-mediated T cell activation. Blood 119(26): 6268-6277.

    2011

    • Arico E, Monque DM, D'Agostino G, Moschella F, Venditti M, Kalinke U, Allen DJ, Nash AA, Belardelli F, Ferrantini M (2011) MHV-68 producing mIFNalpha1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.. Vaccine 29(23): 3935-3944.

    • Buttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, Kramer D, Kropshofer H, Lloyd P, Lubiniecki A, Krause R, Mire-Sluis A, Platts-Mills T, Ragheb JA, Reipert BM, Schellekens H, Seitz R, Stas P, Subramanyam M, Thorpe R, Trouvin JH, Weise M, Windisch J, Schneider CK (2011) Taking immunogenicity assessment of therapeutic proteins to the next level.. Biologicals 39(2): 100-109.

    • Chopy D, Detje CN, Lafage M, Kalinke U, Lafon M (2011) The type I interferon response bridles rabies virus infection and reduces pathogenicity.. J Neurovirol 17(4): 353-367.

    • Dann A, Poeck H, Croxford AL, Gaupp S, Kierdorf K, Knust M, Pfeifer D, Maihoefer C, Endres S, Kalinke U, Meuth SG, Wiendl H, Knobeloch KP, Akira S, Waisman A, Hartmann G, Prinz M (2011) Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci 15(1): 98-106.

    • Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors.. J Exp Med 208(10): 1989-2003.

    • Dominguez PM, Lopez-Bravo M, Kalinke U, Ardavin C (2011) Statins inhibit iNOSmediated microbicidal potential of activated monocyte-derived dendritic cells by an IFNbeta-dependent mechanism.. Eur J Immunol 41(11): 3330-3339.

    • Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B (2011) Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.. Nat Rev Drug Discov 10(7): 495-506.

    • Grabski E, Waibler Z, Schule S, Kloke BP, Sender LY, Panitz S, Cichutek K, Schweizer M, Kalinke U (2011) Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.. Mol Biotechnol 47(3): 262-269.

    • Gratz MS, Suezer Y, Kremer M, Volz A, Majzoub M, Hanschmann KM, Kalinke U, Schwantes A, Sutter G (2011) N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.. J Virol 85(7): 3557-3569.

    • Kalinke U, Bechmann I, Detje CN (2011) Host strategies against virus entry via the olfactory system.. Virulence 2(4): 367-370.

    • Reiss M, Buttel IC, Schneider CK (2011) Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products.. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 54(7): 822-830.

    • Schulke S, Burggraf M, Waibler Z, Wangorsch A, Wolfheimer S, Kalinke U, Vieths S, Toda M, Scheurer S (2011) A fusion protein of flagellin and ovalbumin suppresses the T(H)2 response and prevents murine intestinal allergy.. J Allergy Clin Immunol 128(6): 1340-1348 e1312.

    • Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, Vleminckx C, Wadhwa M, Schneider CK (2011) Biosimilars-why terminology matters.. Nat Biotechnol 29(8): 690-693.

    • Williams SK, Fairless R, Weise J, Kalinke U, Schulz-Schaeffer W, Diem R (2011) Neuroprotective effects of the cellular prion protein in autoimmune optic neuritis.. Am J Pathol 178(6): 2823-2831.

    2010

    • Al Moussawi K, Ghigo E, Kalinke U, Alexopoulou L, Mege JL, Desnues B (2010) Type I interferon induction is detrimental during infection with the Whipple's disease bacterium, Tropheryma whipplei.. PLoS Pathog 6(1): e1000722.

    • Buttel IC, Voller K, Schneider CK (2010) Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals.. Curr Drug Saf 5(4): 287-292.

    • Frenz T, Waibler Z, Hofmann J, Hamdorf M, Lantermann M, Reizis B, Tovey MG, Aichele P, Sutter G, Kalinke U (2010) Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. Eur J Immunol 40(10): 2769-2777.

    • Goetz KB, Pfleiderer M, Schneider CK (2010) First-in-human clinical trials with vaccines-what regulators want.. Nat Biotechnol 28(9): 910-916.

    • Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 12(2): 142-153.

    • Ilchmann A, Burgdorf S, Scheurer S, Waibler Z, Nagai R, Wellner A, Yamamoto Y, Yamamoto H, Henle T, Kurts C, Kalinke U, Vieths S, Toda M (2010) Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: role of macrophage scavenger receptor class A type I and II.. J Allergy Clin Immunol 125(1): 175-183, e171-111.

    • Kern M, Popov A, Scholz K, Schumak B, Dandji D, Limmer A, Eggle D, Sacher T, Zawatzky R, Holtappels R, Reddehase MJ, Hartmann G, Debey-Pascher S, Diehl L, Kalinke U, Koszinowski U, Schultze J, Knolle PA (2010) Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity.. Gastroenterology 138(1): 336-46.

    • Kochs G, Bauer S, Vogt C, Frenz T, Tschopp J, Kalinke U, Waibler Z (2010) Thogoto virus infection induces sustained type I interferon responses that depend on RIG-I-like helicase signaling of conventional dendritic cells.. J Virol 84(23): 12344-12350.

    • Lang PA, Recher M, Honke N, Scheu S, Borkens S, Gailus N, Krings C, Meryk A, Kulawik A, Cervantes-Barragan L, Rooijen NVan, Kalinke U, Ludewig B, Hengartner H, Harris N, Häussinger D, Ohashi PS, Zinkernagel RM, Lang KS (2010) Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice.. Hepatology 51(1): 25-32.

    • Malinarich FH, Grabski E, Worbs T, Chennupati V, Haas JD, Schmitz S, Candia E, Quera R, Malissen B, Forster R, Hermoso M, Prinz I (2010) Constant TCR triggering suggests that the TCR expressed on intestinal intraepithelial gammadelta T cells is functional in vivo. Eur J Immunol 40(12): 3378-88.

    • Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A, Kalinke U, Schwaninger M (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment.. FASEB J 24(3): 788-798.

    • Prinz M, Kalinke U (2010) New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS.. Trends Mol Med 16(8): 379-386.

    • Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftsoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancans J, Maciulaitis R, Robert JL, Samuel A, Ovelgonne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turcani P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schussler-Lenz M, Kokkas V, Buzas Z, MacAleenan N, Galli MC, Line A, Gulbinovic J, Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko M, Marinko P, Timon M, Cheng W, Crosbie GA, Meade N, di Paola ML, VandenDriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Buttel I, Celis P (2010) Challenges with advanced therapy medicinal products and how to meet them.. Nat Rev Drug Discov 9(3): 195-201 Review.

    • Schussler-Lenz M, Schneider CK (2010) Clinical trials with advanced therapy medicinal products.. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53(1): 68-74 Review.

    • Sender LY, Gibbert K, Suezer Y, Radeke HH, Kalinke U, Waibler Z (2010) CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals.. Mol Immunol 47(6): 1255-1261.

    2009

    • Aly S, Mages J, Reiling N, Kalinke U, Decker T, Lang R, Ehlers S (2009) Mycobacteria-induced granuloma necrosis depends on IRF-1. J Cell Mol Med 13(8B): 2069-2082.

    • Anz D, Thaler R, Stephan N, Waibler Z, Trauscheid MZ, Scholz C, Kalinke U, Barchet W, Endres S, Bourquin C (2009) Activation of melanoma differentiation-associated gene 5 causes rapid involution of the thymus. J Immunol 182(10): 6044-6050.

    • Bach P, Tschape JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, Staufenbiel M, Prinz M, Deller T, Kalinke U, Buchholz CJ, Muller UC (2009) Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol 182(12): 7613-7624.

    • Cervantes-Barragan L, Kalinke U, Zust R, Konig M, Reizis B, Lopez-Macias C, Thiel V, Ludewig B (2009) Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol 182(2): 1099-1106.

    • Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B (2009) Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 31(3): 491-501.

    • Dauber B, Martinez-Sobrido L, Schneider J, Hai R, Waibler Z, Kalinke U, Garcia-Sastre A, Wolff T (2009) Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR. PLoS Pathog 5(6): e1000473.

    • Detje CN, Meyer T, Schmidt H, Kreuz D, Rose JK, Bechmann I, Prinz M, Kalinke U (2009) Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol 182(4): 2297-2304.

    • Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458(7240): 904-908.

    • Jahn EM, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. N Biotechnol 25(5): 280-286.

    • Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Lower J, Shafferman A, Sutter G (2009) Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis 199(1): 39-48.

    • Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, Stoiber D, Sexl V, Kolbe T, Rulicke T, Muller M, Decker T, Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, Stoiber D, Sexl V, Kolbe T, Rulicke T, Muller M, Decker T (2009) Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol 183(4): 2286-2293.

    • Richter C, Juan MH, Will J, Brandes RP, Kalinke U, Akira S, Pfeilschifter JM, Hultqvist M, Holmdahl R, Radeke HH (2009) Ncf1 provides a reactive oxygen species-independent negative feedback regulation of TLR9-induced IL-12p70 in murine dendritic cells. J Immunol 182(7): 4183-4191.

    • Schneider CK, Papaluca M, Kurki P (2009) A European perspective on immunogenicity evaluation. Nat Biotechnol 27(6): 507-508.

    • Stockinger S, Kastner R, Kernbauer E, Pilz A, Westermayer S, Reutterer B, Soulat D, Stengl G, Vogl C, Frenz T, Waibler Z, Taniguchi T, Rulicke T, Kalinke U, Muller M, Decker T (2009) Characterization of the interferon-producing cell in mice infected with Listeria monocytogenes. PLoS Pathog 5(3): e1000355.

    • Waibler Z, Anzaghe M, Frenz T, Schwantes A, Pohlmann C, Ludwig H, Palomo-Otero M, Alcami A, Sutter G, Kalinke U (2009) Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol 83(4): 1563-1571.

    2008

    • Michallet MC, Meylan E, Ermolaeva MA, Vazquez J, Rebsamen M, Curran J, Poeck H, Bscheider M, Hartmann G, Konig M, Kalinke U, Pasparakis M, Tschopp J (2008) TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 28(5): 651-661.

    • Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Hacker G, Neuenhahn M, Busch D, Ruland J, Rothenfusser S, Prinz M, Hornung V, Endres S, Tuting T, Hartmann G (2008) 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14(11): 1256-1263.

    • Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, Merkler D, Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Bruck W, Kalinke U (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28(5): 675-686.

    • Schneider CK, Kalinke U (2008) Toward biosimilar monoclonal antibodies. Nat Biotechnol 26(9): 985-990 Review.

    • Schraven B, Kalinke U (2008) CD28 superagonists: what makes the difference in humans?. Immunity 28(5): 591-595.

    • Waibler Z, Anzaghe M, Konur A, Akira S, Muller W, Kalinke U (2008) Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha responses by pDC. Eur J Immunol 38(11): 3127-3137.

    • Waibler Z, Sender LY, Kamp C, Muller-Berghaus J, Liedert B, Schneider CK, Lower J, Kalinke U (2008) Toward experimental assessment of receptor occupancy: TGN1412 revisited. J Allergy Clin Immunol 122(5): 890-892.

    • Waibler Z, Sender LY, Merten C, Hartig R, Kliche S, Gunzer M, Reichardt P, Kalinke U, Schraven B (2008) Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One 3(3): e1708.

    2007

    • Bach P, Kamphuis E, Odermatt B, Sutter G, Buchholz CJ, Kalinke U (2007) Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol 178(9): 5839-5847.

    • Blakqori G, Delhaye S, Habjan M, Blair CD, Sanchez-Vargas I, Olson KE, Attarzadeh-Yazdi G, Fragkoudis R, Kohl A, Kalinke U, Weiss S, Michiels T, Staeheli P, Weber F (2007) La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol 81(10): 4991-4999.

    • Demirel O, Waibler Z, Kalinke U, Grunebach F, Appel S, Brossart P, Hasilik A, Tampe R, Abele R (2007) Identification of a lysosomal peptide transport system induced during dendritic cell development. J Biol Chem 282(52): 37836-37843.

    • Koerner I, Kochs G, Kalinke U, Weiss S, Staeheli P (2007) Protective role of beta interferon in host defense against influenza A virus. J Virol 81(4): 2025-2030.

    • Liedert B, Bassus S, Schneider CK, Kalinke U, Lower J (2007) Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster. Int J Clin Pharmacol Ther 45(1): 1-9.

    • Osterloh A, Kalinke U, Weiss S, Fleischer B, Breloer M (2007) Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J Biol Chem 282(7): 4669-4680.

    • Schleicher U, Liese J, Knippertz I, Kurzmann C, Hesse A, Heit A, Fischer JA, Weiss S, Kalinke U, Kunz S, Bogdan C (2007) NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med 204(4): 893-906.

    • Schneider CK, Kalinke U (2007) After the TGN1412 incident. Principles for assessment of first-in-man trials with monoclonal antibodies by the Paul Ehrlich Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50(10): 1213-1220.

    • Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, Sutter G, Kalinke U (2007) Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 81(22): 12102-12110.

    • Waibler Z, Detje CN, Bell JC, Kalinke U (2007) Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells. Immunobiology 212(9-10): 887-894.

    • Waibler Z, Kalinke U, Will J, Juan MH, Pfeilschifter JM, Radeke HH (2007) TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells. Mol Immunol 44(7): 1483-1489.

    2006

    • Aichele P, Unsoeld H, Koschella M, Schweier O, Kalinke U, Vucikuja S (2006) CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol 176(8): 4525-4529.

    • Buchholz CJ, Bach P, Nikles D, Kalinke U (2006) Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies. Expert Opin Biol Ther 6(3): 293-300.

    • Gerlach N, Schimmer S, Weiss S, Kalinke U, Dittmer U (2006) Effects of type I interferons on Friend retrovirus infection. J Virol 80(7): 3438-3444.

    • Hinz T, Buchholz CJ, van der Stappen T, Cichutek K, Kalinke U (2006) Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother 29(5): 472-476.

    • Kalinke U, Bach P, Konig M, Buchholz CJ (2006) Vaccination against prion diseases. Discov Med 6(31): 29-34.

    • Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U (2006) Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108(10): 3253-3261.

    • Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176(8): 4682-4689.

    • Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176(4): 2074-2078.

    • Ludwig H, Suezer Y, Waibler Z, Kalinke U, Schnierle BS, Sutter G (2006) Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J Gen Virol 87(Pt 5): 1145-1155.

    • Schneider CK, Kalinke U, Lower J (2006) TGN1412--a regulator's perspective. Nat Biotechnol 24(5): 493-496.

    • Schule S, Steidl S, Panitz S, Coulibaly C, Kalinke U, Cichutek K, Schweizer M (2006) Selective gene transfer to T lymphocytes using coreceptor-specific MLV(HIV) pseudotype vectors in a transgenic mouse model. Virology 351(1): 237-247.

    • Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G (2006) Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J Gen Virol 87(Pt 10): 2917-2921.

    2005

    • Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280(35): 30797-30806.

    • Nikles D, Bach P, Boller K, Merten CA, Montrasio F, Heppner FL, Aguzzi A, Cichutek K, Kalinke U, Buchholz CJ (2005) Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 79(7): 4033-4042.

    • Strobl B, Bubic I, Bruns U, Steinborn R, Lajko R, Kolbe T, Karaghiosoff M, Kalinke U, Jonjic S, Muller M (2005) Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol 175(6): 4000-4008.

    2004

    • Meier-Noorden M, Flindt S, Kalinke U, Hinz T (2004) A CpG-rich bidirectional promoter induces the T-cell death-associated gene 51 and downregulates an inversely oriented transcript during early T-cell activation. Gene 338(2): 197-207.

    2003

    • Hangartner L, Senn BM, Ledermann B, Kalinke U, Seiler P, Bucher E, Zellweger RM, Fink K, Odermatt B, Burki K, Zinkernagel RM, Hengartner H (2003) Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.. Proc Natl Acad Sci U S A 100(22): 12883-12888.

    • Senn BM, Lopez-Macias C, Kalinke U, Lamarre A, Isibasi A, Zinkernagel RM, Hengartner H (2003) Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.. Eur J Immunol 33(4): 950-961.

    2002

    • Barchet W, Cella M, Odermatt B, Asselin-Paturel C, Colonna M, Kalinke U (2002) Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo.. J Exp Med 195(4): 507-516.

    • Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K (2002) Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.. J Exp Med 195(12): 1613-1624.

    2001

    • Heppner FL, Arrighi I, Kalinke U, Aguzzi A (2001) Immunity against prions?. Trends Mol Med 7(11): 477-479.

    • Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A (2001) Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294(5540): 178-182.

    • Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, Carroll MC, Verbeek JS, Botto M, Walport MJ, Molina H, Kalinke U, Acha-Orbea H, Aguzzi A (2001) Complement facilitates early prion pathogenesis. Nat Med 7(4): 488-492.

    • Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, McCoy KD, Fehr T, Bachmann MF, Kalinke U, Hengartner H (2001) Neutralizing antiviral antibody responses. Adv Immunol (79): 1-53.

    2000

    • Kalinke U, Oxenius A, Lopez-Macias C, Zinkernagel RM, Hengartner H (2000) Virus neutralization by germ-line vs. hypermutated antibodies. Proc Natl Acad Sci U S A 97(18): 10126-10131.

    • Karrer U, Lopez-Macias C, Oxenius A, Odermatt B, Bachmann MF, Kalinke U, Bluethmann H, Hengartner H, Zinkernagel RM (2000) Antiviral B cell memory in the absence of mature follicular dendritic cell networks and classical germinal centers in TNFR1-/- mice. J Immunol 164(2): 768-778.

    • Seiler P, Senn BM, Klenerman P, Kalinke U, Hengartner H, Zinkernagel RM (2000) Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. J Virol 74(13): 5896-5901.

    1999

    • Lopez-Macias C, Kalinke U, Cascalho M, Wabl M, Hengartner H, Zinkernagel RM, Lamarre A (1999) Secondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses. J Exp Med 189(11): 1791-1798.

    • Seiler P, Senn BM, Brundler MA, Zinkernagel RM, Hengartner H, Kalinke U (1999) In vivo selection of neutralization-resistant virus variants but no evidence of B cell tolerance in lymphocytic choriomeningitis virus carrier mice expressing a transgenic virus-neutralizing antibody. J Immunol 162(8): 4536-4541.

    1998

    • Funk GA, Barbour AD, Hengartner H, Kalinke U (1998) Mathematical model of a virus-neutralizing immunglobulin response. J Theor Biol 195(1): 41-52.

    • Seiler P, Kalinke U, Rulicke T, Bucher EM, Bose C, Zinkernagel RM, Hengartner H (1998) Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice. J Virol 72(3): 2253-2258.

    1997

    • Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Hoost H, Aguet M, Hengartner H, Zinkernagel RM (1997) The role of antibody concentration and avidity in antiviral protection. Science 276(5321): 2024-2027.

    • Fehr T, Bachmann MF, Bucher E, Kalinke U, Di Padova FE, Lang AB, Hengartner H, Zinkernagel RM (1997) Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185(10): 1785-1792.

    • Hammami-Hauasli N, Kalinke DU, Schumann H, Kalinke U, Pontz BF, Anton-Lamprecht I, Pulkkinen L, Zimmermann M, Uitto J, Bruckner-Tuderman L (1997) A combination of a common splice site mutation and a frameshift mutation in the COL7A1 gene: absence of functional collagen VII in keratinocytes and skin. J Invest Dermatol 109(3): 384-389.

    • Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, Bluethmann H, Bootz F, Suter M, Zinkernagel RM, Aguzzi A (1997) A crucial role for B cells in neuroinvasive scrapie. Nature 390(6661): 687-690.

    1996

    • Battegay M, Fiedler P, Kalinke U, Brombacher F, Zinkernagel RM, Peter HH, Kohler G, Eibel H (1996) Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mic. Eur J Immuno 26(1): 250-258.

    • Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost HP, Geley S, Kofler R, Zinkernagel RM, Hengartner H (1996) The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis viru. Immunity 5(6): 639-652.

    • Kalinke U, Krebber A, Krebber C, Bucher E, Pluckthun A, Zinkernagel RM, Hengartner H (1996) Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. Eur J Immuno 26(12): 2801-2806.

    1995

    • Gilfillan S, Bachmann M, Trembleau S, Adorini L, Kalinke U, Zinkernagel R, Benoist C, Mathis D (1995) Efficient immune responses in mice lacking N-region diversity. Eur J Immunol 25(11): 3115-3122.

    • Roost HP, Bachmann MF, Haag A, Kalinke U, Pliska V, Hengartner H, Zinkernagel RM (1995) Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci 92(5): 1257-1261.

    1994

    • Kalinke DU, Kalinke U, Winberg JO, Konig A, Lauharanta J, Christiano AM, Uitto J, Bruckner-Tuderman L (1994) Collagen VII in severe recessive dystrophic epidermolysis bullosa: expression of mRNA but lack of intact protein product in skin and cutaneous cells in vitro. J Invest Dermatol 102(2): 260-262.

    1991

    • Schonrich G, Kalinke U, Momburg F, Malissen M, Schmitt-Verhulst AM, Malissen B, Hammerling GJ, Arnold B (1991) Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance inductio. Cell 65(2): 293-304.

    1990

    • Kalinke U, Arnold B, Hammerling GJ (1990) Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 domain into HLA B27. Nature 348(6302): 642-644.